meta|evidence oncology

Living systematic review and meta-analysis

metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population 9
mML - NA - PDL1 positive 1
mML - 1st line (L1)
mML - L1 - all population 7
mML - L1 - BRAF mutant 2
mML - L1 - BRAF wild 3
mML - 2nd line (L2)
mML - L2 - all population 11
mML - L2 - BRAF mutant 1
mesothelioma (MS)

immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
Ipilimumab (10 mg/kg)
ipilimumab plus gp100
ipilimumab plus SoC
tremelimumab
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus cometinib
atezolizumab plus SoC
nivolumab based treatment
nivolumab alone
nivolumab followed by ipilimumab
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab (10mg/kg)
pembrolizumab (10mg/kg) 2 weeks
pembrolizumab (2mg/kg)
pembrolizumab plus SoC
Immune checkpoint association
nivolumab plus ipilimumab
relatlimab plus nivolumab

versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs alkylating agents
vs dacarbazine
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs Ipilimumab (10 mg/kg)
vs ipilimumab followed by nivolumab
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
vs pembrolizumab based treatment
vs pembrolizumab alone
vs Immunostimulant
vs interferon alpha
vs vaccine
vs gp100
vs non active control
vs placebo

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
Empty list - no studies excluded

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -